Vertex Pharmaceuticals Incorporated
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Reshma Kewalramani
- Full Time Employees
- 6,100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Northern Avenue Boston MA United States of America 02210
- IPO Date
- Jul 24, 1991
- CIK
- 0000875320
- Website
- vrtx.com
- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts and founded in 1989, develops, manufactures and commercializes transformative medicines for serious diseases, with a primary focus on cystic fibrosis, sickle cell disease, beta thalassemia and emerging areas including pain, kidney disease and type 1 diabetes; its portfolio features the CFTR modulators TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, the CRISPR/Cas9 gene-edited therapy CASGEVY (co-developed with CRISPR Therapeutics), the non-opioid NaV1.7 pain treatment JOURNAVX/suzetrigine, and investigational assets such as povetacicept (for IgA nephropathy and other autoimmune kidney diseases), inaxaplin (for APOL1-mediated kidney disease), VX-407 (for autosomal dominant polycystic kidney disease), VX-522 (CFTR mRNA therapy with Moderna), VX-880/VX-264 (stem cell therapies for type 1 diabetes) and VX-993 (next-generation pain candidate); the company operates research facilities in San Diego, California and Milton Park, Oxfordshire, UK, with commercial presence across North America, Europe, Australia, Asia and the Middle East. In recent developments, Vertex completed its $4.9 billion acquisition of Alpine Immune Sciences in 2024 to secure povetacicept, entered an exclusive collaboration with Ono Pharmaceutical in June 2025 for povetacicept commercialization in Japan and South Korea (building on a prior deal with Zai Lab), launched ALYFTREK in the US and began European reimbursement efforts in England, Germany and Denmark, advanced CASGEVY and JOURNAVX launches with expanding US coverage including major PBMs and hospital networks, completed Phase 3 enrollment for povetacicept in IgA nephropathy (targeting accelerated US approval in H1 2026), initiated VX-407 Phase 2 proof-of-concept for ADPKD, progressed VX-522 Phase 1/2 data readout in H1 2025 and discontinued standalone development of an experimental pain drug following mid-stage failure while prioritizing suzertrigine/JOURNAVX expansion. Vertex reported Q3 2025 total revenues of $3.08 billion (up 11% year-over-year), driven by CF franchise growth, early new product contributions and favorable US pricing, with full-year 2025 guidance refined to $11.9-12.0 billion.
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
US FDA approves Vertex's gene therapy for sickle cell disease in children as young as two
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions